Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Leicester
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Leicester, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca16 Hoffmann-La Roche14 Merck Sharp & Dohme LLC13 Boehringer Ingelheim9 Sanofi9
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Leicester

208 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
Boehringer Ingelheim
Phase 3
600
Leicester
2026-10-23
Not yet open
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
DrugsZL-1310·Obrixtamig·Atezolizumab
Boehringer Ingelheim
Phase 1/2
60
Leicester, Newcastle upon Tyne
2026-10-19
Not yet open
Medtronic MiniMed, Inc.
Not applicable
230
Cambridge, Leicester, Manchester
2026-10-15
Recruiting
Boehringer Ingelheim
Phase 3
466
Birmingham, Exeter, Lancaster, Leeds, Leicester, London, Manchester, Oxford
2026-09-17
Recruiting
CSL Behring
Phase 3
63
London, Leicester
2026-09-15
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365Geographic Atrophy
DrugSTL303
Sitala Bio LTD
Phase 2
300
London, Southampton, Leicester, Newcastle upon Tyne
2026-09-11
Recruiting
Takeda
Phase 3
324
Lincoln, Leicester, London, Sunderland, Birmingham
2026-09-10
Recruiting
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT07665515Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Epitopea Ltd
Phase 1
50
Cambridge, Edinburgh, Glasgow, Leeds, Leicester, London, Preston, Sutton
2026-09
Recruiting
Kardigan, Inc.
Phase 3
332
Bristol, Glasgow, Leicester, London, Oxford
2026-08-26
Recruiting
AstraZeneca
Phase 3
7,000
Aberdeen, Cardiff, Corby, Coventry, Dundee, Glasgow, Leicester, Liverpool
2026-08-21
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Cambridge, Cardiff, Glasgow, Leicester, London, Manchester, Newcastle, Salford
2026-08-05
Active, closed
Boehringer Ingelheim
Phase 2
344
Blackpool, Guisborough, High Wycombe, Leicester, Middlesbrough, Oxford
2026-06-30
Recruiting
AstraZeneca
Phase 3
4,500
Ashton-under-Lyne, Blackpool, Chesterfield, Corby, Ely, Glasgow, Hounslow, Leicester
2026-06-29
Recruiting
GlaxoSmithKline
Phase 3
600
Sutton, Leicester, London
2026-06-04
Recruiting
Bayer
Phase 3
117
Leicester, Liverpool, Belfast, Glasgow, Newcastle upon Tyne, Leeds, Bristol
2026-06-01
Recruiting
Regeneron Pharmaceuticals
Phase 3
270
Truro, Norwich, Leicester
2026-05-21
Recruiting
Hoffmann-La Roche
Phase 2/3
650
Leicester, Liverpool, London, Manchester, Montacute
2026-05-21
Recruiting
Alfasigma S.p.A.
Phase 3
65
Bristol, Leicester, Nottingham
2026-05-21
Recruiting
Takeda
Phase 3
300
Leicester, Boston, Oxford, Birmingham, London, Manchester
2026-05-21
Recruiting
Mirati Therapeutics Inc.
Phase 2
170
London, Birmingham, Leicester
2026-05-06
Recruiting
UK PureWick™ At-Home Pilot Study
NCT07555548Urinary Incontinence
Becton, Dickinson and Company
Observational
95
Doncaster, Leicester, Northampton, Norwich
2026-05-06
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Cambridge, Edinburgh, Glasgow, Leicester, Withington, Birmingham, Cardiff, Southampton
2026-04-09
Recruiting
Hoffmann-La Roche
Phase 2
80
Leicester, London, Manchester
2026-04-07
Recruiting
PS-002 for the Treatment of IgA Nephropathy in Adults
NCT07182227Immunoglobulin A (IgA) Nephropathy
Purespring Therapeutics Limited
Phase 1/2
32
Manchester, Leicester, Nottingham, Bristol, Cardiff, Edinburgh, London
2026-03-30
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
DrugsTiespectus·Eylea·Aflibercept
EyeBiotech Ltd.
Phase 2/3
960
Leicester, Liverpool, London
2026-03-27
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Soham, Chippenham, Airdrie, Birmingham, Glasgow, Leicester, London, Newcastle upon Tyne
2026-03-16
Recruiting
Avalyn Pharma Inc.
Phase 2
160
Exeter, Cottingham, Leicester, Birmingham
2026-03-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Cambridge, Leicester, London, Manchester
2026-02-16
Recruiting
Boehringer Ingelheim
Phase 3
286
Bebington, Bradford, Cambridge, Carshalton, Leicester, London, Middlesbrough, Salford
2026-02-16
Recruiting
Kardigan, Inc.
Phase 2/3
332
Bristol, Glasgow, Leicester, London, Oxford
2026-02-13
Recruiting
Kymera Therapeutics, Inc.
Phase 2
264
Bedford, Birmingham, Bristol, Leicester, London, Wythenshawe
2026-01-28
Active, closed
Kailera
Phase 3
1,270
Truro, Plymouth, Bournemouth, Hull, Glasgow, London, Stevenage, Leicester
2026-01-12
Recruiting
Contineum Therapeutics
Phase 2
324
Leicester, London, Southampton, Edinburgh, Perth, Birmingham
2026-01-08
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Leicester, London
2026-01-02
Active, closed
Kailera
Phase 3
1,270
Exeter, Torquay, Weymouth, Glasgow, London, Leicester, Rotherham
2025-12-30
Active, closed
Kailera
Phase 3
2,530
Soham, Torpoint, Hull, Stevenage, Leicester, Nottingham, Newcastle upon Tyne, Bradford
2025-12-18
Recruiting
Hoffmann-La Roche
Phase 2
160
Leicester, Doncaster, Newcastle upon Tyne, Barnet
2025-12-05
Recruiting
GlaxoSmithKline
Phase 1
83
Leicester, London, Sutton
2025-12-03
Recruiting
Hoffmann-La Roche
Phase 3
250
Leicester, Gloucester, London
2025-11-27
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 2
75
Birmingham, Cambridge, Leicester, London, Manchester
2025-11-26
Recruiting
Bayer
Phase 3
111
Leicester, Liverpool, Belfast, Glasgow, Newcastle upon Tyne, Leeds, Bristol
2025-11-19
Recruiting
Boehringer Ingelheim
Phase 3
670
Cardiff, Leicester, Manchester, Sutton, Torquay
2025-11-07
Recruiting
Pharvaris Netherlands B.V.
Phase 3
48
Bristol, Cambridge, Leicester, London, Newcastle upon Tyne, Plymouth
2025-10-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Truro, London, Birmingham, Leicester
2025-10-08
Recruiting
Sanofi
Phase 4
218
Dundee, Newcastle upon Tyne, Southampton, Leicester, Bradford, Sheffield
2025-09-22
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 2
30
Cambridge, Leicester, London, Salford
2025-09-19
Recruiting
Sanofi
Phase 3
942
Bristol, London, Leicester, Harrow, Oxford, Worthing, Bradford
2025-09-16
Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)
ADARx Pharmaceuticals, Inc.
Phase 2
45
Leicester, Newcastle upon Tyne
2025-08-28
Recruiting
Takeda
Phase 3
150
Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London
2025-08-14
Recruiting
Eli Lilly and Company
Phase 1/2
68
Bristol, Leeds, Leicester, London
2025-07-30
Recruiting
Study of BHV-1400 in IgA Nephropathy
NCT07054684IgA Nephropathy
Biohaven Therapeutics Ltd.
Phase 1
20
Leicester
2025-07-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
London, Leicester, Manchester
2025-07-21
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Cambridge, Edinburgh, Leicester, Newcastle upon Tyne
2025-07-16
Active, closed
Aligos Therapeutics
Phase 2
200
Glasgow, Leicester, London
2025-07-15
Recruiting
Takeda
Phase 3
347
London, Birmingham, Canterbury, Hull, Leicester, Nottingham, Preston, Sheffield
2025-07-15
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
London, Dundee, Huddersfield, Colchester, Orpington, Nottingham, Blackpool, Leicester
2025-06-30
Active, closed
DBV Technologies
Phase 3
480
Glasgow, Leicester, London, Manchester, Sheffield, Southampton
2025-06-24
Active, closed
Incyte Corporation
Phase 3
9
Cardiff, Glasgow, Leeds, Leicester, London
2025-06-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
East Sussex, Cambridge, Glasgow, London, Edinburgh, Leicester, Maidstone, Manchester
2025-05-22
Recruiting
SecuraBio
Phase 3
124
Sutton, Glasgow, Leicester, London, Manchester, Nottingham, Oxford
2025-05-19
Recruiting
Biogen
Phase 3
454
London, Preston, Leicester, Sheffield, Stoke-on-Trent
2025-05-08
Active, closed
FARAPULSE Workflow Assessment Registry
NCT06656884Atrial Fibrillation (AF)
Boston Scientific Corporation
Observational
524
Bournemouth, Cambridge, Leicester, Newcastle upon Tyne, Southampton
2025-05-06
Recruiting
Takeda
Phase 3
225
Aberdeen, Rhyl, Leicester, Lincoln, High Heaton, Sunderland, Birmingham, Cambridge
2025-05-06
Active, closed
Hoffmann-La Roche
Phase 2
285
Blackpool, Leicester, Shipley, Coventry, Northwood, Orpington
2025-05-05
Recruiting
Vanda Pharmaceuticals
Phase 3
420
Great Yarmouth, Leicester, Liverpool, London, Sheffield
2025-04-21
Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Phase 2
340
Cottingham, Oxford, Birmingham, Cambridge, Leicester, London
2025-04-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Cambridge, Edinburgh, Preston, London, Sutton, Birmingham, Leicester, Liverpool
2025-04-09
Recruiting
FORWARD CAD IDE Study
NCT06662500Coronary Arterial Disease (CAD)
Shockwave Medical, Inc.
Not applicable
408
Basildon, Bristol, Leeds, Leicester, London
2025-04-04
Active, closed
Amgen
Phase 3
1,105
Belfast, Birmingham, Blackpool, Bristol, Ely, Glasgow, Hull, Leicester
2025-03-17
Recruiting
AbbVie
Phase 1/2
252
Leicester, Cardiff
2025-03-06
Recruiting
Takeda
Phase 3
171
Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London
2025-02-27
Recruiting
Maze Therapeutics
Phase 2
74
Leicester, London
2025-02-05
Recruiting
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
NCT06789172Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
DrugFamotidine
Epkin
Phase 1
146
Glasgow, Leicester, London, Manchester, Oxford
2025-01-23
By invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543·Ibrutinib
Janssen Research & Development, LLC
Phase 1
120
Leicester, London, Plymouth
2024-12-30
Recruiting
Sanofi
Phase 2
84
Leicester, Salford, Oxford
2024-12-19
Recruiting
GlaxoSmithKline
Phase 3
520
Leicester, Middlesbrough, Oxford, Plymouth, Wolverhampton
2024-12-16
Active, closed
Hoffmann-La Roche
Phase 3
350
Leicester, Llanrhystud, London, Stockport
2024-12-11
Recruiting
OSE Immunotherapeutics
Phase 3
363
Leicester, Manchester, Metropolitan Borough of Wirral, Sutton, Aberdeen
2024-12-03
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
DrugTaladegib
Endeavor Biomedicines, Inc.
Phase 2
213
Belfast, Birmingham, Cambridge, Edinburgh, Exeter, Leicester, London, Londonderry
2024-11-15
Active, closed
Janssen Research & Development, LLC
Phase 1
19
Leicester
2024-10-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Bristol, London, Nottingham, Leeds, Leicester, Manchester, Metropolitan Borough of Wirral, Portsmouth
2024-10-21
Recruiting
argenx
Phase 3
69
Birmingham, Bradford, Coventry, Glasgow, Leicester, London, Truro
2024-10-18
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Exeter, Dundee, Larbert, Glasgow, London, Leicester, Manchester, Metropolitan Borough of Wirral
2024-10-07
Recruiting
AstraZeneca
Phase 3
744
Birmingham, Cambridge, Glasgow, Leicester, London, Manchester, Middlesbrough
2024-10-04
Active, closed
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
DrugSotagliflozin
Lexicon Pharmaceuticals
Phase 3
500
Glasgow, Leicester, Liverpool, London
2024-09-24
Recruiting
GlaxoSmithKline
Phase 3
440
Leicester, Birmingham, London
2024-09-11
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Belfast, Birmingham, Bristol, Cambridge, Glasgow, Gloucester, Leicester, London
2024-08-30
Active, closed
Gilead Sciences
Phase 3
640
Birmingham, Cambridge, Leeds, Leicester, London, Northwood
2024-08-28
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
93
Leicester, London, Swansea
2024-08-26
Recruiting
Jazz Pharmaceuticals
Phase 3
550
Bath, Glasgow, Leicester, London, Manchester, Oxford, Wolverhampton
2024-08-13
Recruiting
Study of XB010 in Subjects With Solid Tumors
NCT06545331Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer)
DrugPembrolizumab
Exelixis
Phase 1
396
Leicester, London, Manchester
2024-08-06
Recruiting
NovoCure GmbH
Phase 3
734
London, Leicester, Liverpool, Sutton
2024-07-31
Recruiting
Study of WAL0921 in Patients With Glomerular Kidney Diseases
NCT06466135Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
Walden Biosciences
Phase 2
96
Derby, Leicester, London, Manchester, Salford
2024-07-02
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Birmingham, Boston, Cambridge, Cardiff, Edinburgh, Gloucester, Harrogate, Leicester
2024-06-03
Recruiting
Eli Lilly and Company
Phase 3
300
Cambridge, Glagow, Leeds, Leicester, Liverpool, London, Newcastle upon Tyne, Sheffield
2024-06-03
Active, closed
Stealth BioTherapeutics Inc.
Phase 3
313
Bristol, Leicester, London, Sunderland
2024-05-30
Active, closed
Sanofi
Phase 3
1,541
Portsmouth, Leicester, London, Glasgow
2024-05-08
Recruiting
W.L.Gore & Associates
Observational
2,000
Leicester, Liverpool, London
2024-05-07
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Cambridge, Doncaster, Leicester, London, Manchester, Reading, Stevenage
2024-03-29
Active, closed
AstraZeneca
Phase 3
2,554
Bristol, Cambridge, Dundee, Glasgow, Harrow, Hounslow, Leicester, Liverpool
2024-03-29
Recruiting
Verastem, Inc.
Phase 3
270
Glasgow, Cambridge, Edinburgh, Leicester, London, Manchester, Sutton
2024-03-18
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Reading, Portadown, Edinburgh, Leicester, Liverpool, London, Londonderry, Manchester
2024-03-07
Recruiting
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
NCT06209736C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis
DrugOMS906 study drug
Omeros Corporation
Phase 2
20
Leicester, Newcastle upon Tyne
2024-03-01
Active, closed
Boehringer Ingelheim
Phase 1
69
Leicester
2024-02-14
Active, closed
Boehringer Ingelheim
Phase 3
428
Edinburgh, Leicester, London, Sutton
2024-02-09
By invitation
Sanofi
Phase 3
90
Birmingham, Leicester, London, Bradford
2024-01-03
Active, closed
Sanofi
Phase 2
197
Cambridge, Dundee, Birmingham, Glasgow, Leicester, Harrow
2023-12-11
Active, closed
Incyte Corporation
Phase 3
450
Ipswich, Leicester, London, Nottingham, Walsall
2023-11-27
Active, closed
Genentech, Inc.
Phase 1
65
Cambridge, Leicester, London, Oxford, Sutton
2023-11-27
Recruiting
AstraZeneca
Phase 3
625
Cardiff, Chelsea, Leicester, Liverpool, London, Oxford, Surrey, Sutton
2023-11-23
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Leicester, Nottingham, Taunton, Bodelwyddan, London
2023-11-16
Active, closed
AstraZeneca
Phase 3
863
Cambridge, Leeds, Leicester, London, Manchester, Newcastle upon Tyne, Portsmouth, Taunton
2023-11-09
Active, closed
Ipsen
Observational
1,057
Leicester, Liverpool, London, Middlesbrough, Nottingham
2023-11-01
Recruiting
Orion Corporation, Orion Pharma
Phase 1/2
315
Leicester, London, Sheffield
2023-10-26
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Leicester, London, Manchester, Newcastle upon Tyne
2023-10-13
Active, closed
Enlighten Study: The EV-ICD Post Approval Registry
NCT06048731Ventricular Arrhythmia, Tachycardia
Medtronic
Observational
1,000
Leicester, London
2023-09-01
Recruiting
AstraZeneca
Phase 3
231
Birmingham, Bradford, Bristol, Glasgow, Leicester, London, Nottingham, Stoke-on-Trent
2023-08-24
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
437
Leicester, London
2023-08-10
Active, closed
Hoffmann-La Roche
Phase 3
459
Cambridge, Leicester, London, Oxford, Salford
2023-08-08
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Bristol, Brighton, Salford, Leicester, London, Nottingham
2023-07-06
Active, closed
OncoC4, Inc.
Phase 3
630
Birmingham, Cambridge, Exeter, Leicester, London, Middlesbrough, Torquay, Manchester
2023-06-28
Active, closed
Viatris Innovation GmbH
Phase 3
451
Leicester, London
2023-06-26
Recruiting
GlaxoSmithKline
Phase 1/2
123
Leicester, Oxford, Plymouth
2023-06-14
Active, closed
AbbVie
Phase 1
135
Cambridge, Leicester, London
2023-06-09
Active, closed
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Alexion Pharmaceuticals, Inc.
Phase 3
165
Leicester, Norwich, Oxford
2023-06-07
Recruiting
Hoffmann-La Roche
Phase 3
100
Leicester, Surrey
2023-06-01
Recruiting
Genentech, Inc.
Phase 1
210
Cambridge, Leicester, Manchester, Sutton
2023-05-02
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Leicester, London, Metropolitan Borough of Wirral
2023-02-06
Active, closed
Janssen Research & Development, LLC
Phase 3
213
Leeds, Leicester, Surrey, Wolverhampton
2022-12-15
Recruiting
AstraZeneca
Phase 3
3,527
Bristol, Dundee, Glasgow, Hampshire, Huddersfield, Leeds, Leicester, London
2022-12-13
Recruiting
Janssen Research & Development, LLC
Phase 2
520
Cheltenham, Devon, Edinburgh, Leicester, London, Nottingham, Portsmouth
2022-11-11
Recruiting
Pfizer
Phase 3
1,060
Leicester, London, Edinburgh, Oxford, Stoke-on-Trent, Birmingham, Cardiff, Glasgow
2022-11-10
Recruiting
Bristol-Myers Squibb
Phase 1/2
260
Manchester, Leicester, Liverpool, Oxford, London
2022-10-18
Recruiting
Celgene
Phase 3
810
Cambridge, Truro, Airdrie, London, Leicester, Barnet, Newcastle upon Tyne, Stoke-on-Trent
2022-09-20
Recruiting
GlaxoSmithKline
Phase 3
109
Leicester
2022-09-06
Recruiting
Stemline Therapeutics, Inc.
Phase 1/2
73
Leicester, Liverpool, London, Manchester
2022-08-31
Active, closed
Sanofi
Phase 2/3
1,856
Bristol, London, Glasgow, Portsmouth, Leicester, Nottingham, Liverpool
2022-08-22
Recruiting
Novartis Pharmaceuticals
Phase 2
240
Cambridge, Leicester
2022-08-10
Recruiting
Step Pharma, SAS
Phase 1/2
180
Leicester, London, Manchester, Nottingham, Oxford, Plymouth, Sutton
2022-08-03
Active, closed
Eli Lilly and Company
Phase 4
780
Aberdeen, Dundee, Ely, Plymouth, Hull, Leicester, Rotherham
2022-08-01
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
Bristol, Leicester, London, Swansea
2022-07-22
Active, closed
Daiichi Sankyo
Phase 3
586
Birmingham, Glasgow, Leeds, Leicester, London, Manchester, Wolverhampton
2022-07-08
Active, closed
Sanofi
Phase 3
531
Derby, Birmingham, Leicester, London, Norwich
2022-06-23
Recruiting
Dimerix Bioscience Pty Ltd
Phase 3
286
Birmingham, Bristol, Canterbury, Carshalton, Coventry, Glasgow, Leicester, London
2022-05-30
Active, closed
Verastem, Inc.
Phase 1/2
153
Leicester, London, Sutton
2022-04-12
By invitation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Leicester, London
2022-04-05
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
466
Basildon, Bellshill, Birmingham, Carshalton, Leicester, London, Manchester, Nottingham
2022-03-30
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Cambridge, Gloucester, Leicester, London, Salford, Swansea
2022-03-15
Active, closed
Janssen Research & Development, LLC
Phase 2
151
Leicester, London
2022-03-01
Recruiting
Shockwave Medical, Inc.
Not applicable
380
Basildon, Birmingham, Bristol, Cambridge, Dorchester, Kettering, Leicester, Liverpool
2022-01-04
Active, closed
Merck Sharp & Dohme LLC
Phase 3
643
East Sussex, Cambridge, Truro, Kendal, Dundee, Leicester, London, Cardiff
2021-12-13
Active, closed
Hoffmann-La Roche
Phase 3
660
Blackpool, GB Manchester, Hull, Leeds, Leicester, London
2021-11-18
Active, closed
Gilead Sciences
Phase 3
603
Birmingham, Colchester, Glasgow, Leeds, Leicester, London, Manchester
2021-11-17
Active, closed
AstraZeneca
Phase 3
148
Leicester, London
2021-10-28
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Birmingham, Leeds, Leicester, London, Oxford, Plymouth
2021-09-20
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Newcastle upon Tyne, Cambridge, Leicester, London, Salford
2021-09-20
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Leicester, London, Nottingham, Preston
2021-08-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Truro, Leicester, London, Manchester, Blackpool, Londonderry
2021-06-18
Active, closed
The SELUTION DeNovo Study
NCT04859985Coronary Artery Disease
M.A. Med Alliance S.A.
Not applicable
3,326
Stoke-on-Trent, Bournemouth, Brighton, Bristol, Edinburgh, Glasgow, Leicester, Manchester
2021-05-15
Recruiting
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures
NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis
AgNovos Healthcare, LLC
Not applicable
2,400
Birmingham, Leicester, Edinburgh, Glasgow, Manchester, Nottingham
2021-04-24
Active, closed
Incyte Corporation
Phase 3
654
Birmingham, Bristol, Leicester, London, Manchester, Middlesbrough, Sutton, Wolverhampton
2021-04-15
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Birmingham, Edinburgh, Glasgow, Leicester, Manchester
2021-02-23
Recruiting
Biosense Webster, Inc.
Observational
8,000
Leicester, London
2021-02-22
Active, closed
M.A. Med Alliance S.A.
Not applicable
723
Frimley, Leicester, London, Redhill
2021-02-08
Active, closed
Forma Therapeutics, Inc.
Phase 3
450
Leicester, London, Oxford, Sheffield
2021-01-29
Recruiting
BioInvent International AB
Phase 1/2
250
Birmingham, Leicester, London, Manchester, Southampton
2021-01-25
Recruiting
Pfizer
Phase 3
2,100
Leicester, London
2021-01-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Bristol, Cottingham, Glasgow, London, Sutton, Leicester, Manchester
2021-01-10
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Bristol, Hertford, Leicester, London, Salford
2020-12-11
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Birmingham, Edinburgh, Kent, Leicester, London, Manchester, Surrey
2020-12-02
Active, closed
AstraZeneca
Phase 3
957
Cambridge, Dundee, Glasgow, Leicester, London, Manchester, Oxford, Surrey
2020-11-17
Active, closed
CHAMPION-AF Clinical Trial
NCT04394546Atrial Fibrillation, Stroke, Bleeding
DrugsNon-Vitamin K Anticoagulant·NOAC
Boston Scientific Corporation
Not applicable
3,000
Brighton, Leicester, Oxford
2020-10-15
Active, closed
Hoffmann-La Roche
Phase 3
992
Brighton, Leicester, London, Maidstone, Peterborough, Plymouth, Sutton, Truro
2020-10-09
Active, closed
Sanofi
Phase 3
337
Bournemouth, London, Leicester, Southampton
2020-06-16
Active, closed
AstraZeneca
Phase 2
240
Derby, Leicester
2020-04-22
Active, closed
Takeda
Phase 3
354
London, Sutton, Bebington, Leicester, Manchester
2020-01-10
Active, closed
GlaxoSmithKline
Phase 1
118
Leicester, Oxford, Southampton
2019-12-18
Active, closed
Foundry Innovation & Research 1, Limited (FIRE1)
Not applicable
50
Bournemouth, Glasgow, Leicester, London, Portsmouth, Southampton
2019-11-22
Active, closed
AstraZeneca
Phase 3
140
Cambridge, Leicester, London, Portsmouth
2019-10-29
Active, closed
AstraZeneca
Phase 4
75
Cambridge, Headington, Leicester, Liverpool, London, Wythenshawe
2019-10-08
Active, closed
Applied Therapeutics, Inc.
Phase 3
675
Dundee, Glasgow, Leicester, London, Manchester
2019-09-20
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Bath, Leicester, London, Manchester, Oxford, Southampton, Sutton, Taunton
2019-09-18
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
DrugsVenclexta·Venetoclax
AbbVie
Phase 3
165
Plymouth, Leicester, London, Southampton, Blackpool, Liverpool, Wolverhampton
2019-09-06
Active, closed
Hoffmann-La Roche
Phase 1/2
498
Leicester, London
2019-08-13
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
DrugsIxazomib·Elranatamab·Teclistamab·Pomalidomide
CellCentric Ltd.
Phase 1/2
250
Sutton, Bebington, Bristol, Cardiff, Derby, Edinburgh, Glasgow, Leicester
2019-08-09
Active, closed
AstraZeneca
Phase 3
587
Cambridge, Leicester, Liverpool, Maidstone, Manchester
2019-07-02
Recruiting
HighLife SAS
Not applicable
120
Belfast, Brighton, Edinburgh, Leeds, Leicester, London, Oxford
2019-05-28
Active, closed
Zynerba Pharmaceuticals, Inc.
Phase 2/3
476
Leicester, Edinburgh, Manchester
2018-11-09
Recruiting
AtriCure, Inc.
Observational
5,000
Leicester
2018-06-29
Active, closed
Hoffmann-La Roche
Phase 1/2
211
Leicester, London, Newcastle upon Tyne
2018-05-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Leicester, Metropolitan Borough of Wirral, London, Sutton, Nottingham, Birmingham, Newcastle upon Tyne, Plymouth
2018-04-24
Active, closed
AstraZeneca
Phase 2
273
Aberdeen, Bristol, Cardiff, Durham, Edinburgh, Leicester, London, Manchester
2018-03-07
Recruiting
LivaNova
Observational
500
Leicester, London, Newcastle upon Tyne, Wells
2017-12-14
Active, closed
AstraZeneca
Phase 3
1,186
Leicester, London, Manchester
2017-06-01
Active, closed
Acerta Pharma BV
Phase 3
310
Birmingham, Cambridge, Canterbury, Leicester, London, Maidstone, Manchester, Southampton
2017-02-02
Active, closed
Acerta Pharma BV
Phase 3
533
Birmingham, Bournemouth, Cambridge, Cardiff, Greater London, Hull, Leeds, Leicester
2015-07-28
Active, closed
Taiho Oncology, Inc.
Phase 1/2
253
Leicester, Southampton, Oxford, Sutton, Birmingham, Glasgow, London, Manchester
2015-07-14
Active, closed
Medtronic
Observational
3,100
Birmingham, Bristol, Leeds, Leicester, Liverpool, London, Manchester, Middlesbrough
2015-07
Active, closed
Acerta Pharma BV
Phase 3
535
Bournemouth, Cambridge, Leeds, Leicester, London, Plymouth, Southampton, Truro
2015-06-26
Active, closed
Acerta Pharma BV
Phase 2
124
Cardiff, Leeds, Leicester, Nottingham, Oxford, Plymouth, Southampton
2015-03-02
Active, closed
ViiV Healthcare
Phase 3
371
Bournemouth, Leicester, London
2015-02-23
By invitation
Registry of Patients With Hypophosphatasia
NCT02306720Hypophosphatasia (HPP)
Alexion Pharmaceuticals, Inc.
Observational
1,571
Bristol, London, Leicester, Stanmore, Oxford, Sheffield, Newcastle upon Tyne, Birmingham
2015-01-20
Active, closed
Acerta Pharma BV
Phase 2
107
Bournemouth, Leeds, Leicester, London, Oxford, Plymouth, Southampton
2014-09-11
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
Birmingham, Bournemouth, Colchester, Glasgow, Leeds, Leicester, London, Manchester
2013-09-09
Active, closed
MedImmune LLC
Phase 2
571
Leeds, Leicester, London, Maidstone, Manchester, Metropolitan Borough of Wirral, Plymouth, Southampton
2013-05-17
Active, closed
Medtronic Cardiovascular
Not applicable
1,746
Leeds, Leicester, London
2012-04
Recruiting
Exactech Shoulder Post Market Clinical Follow-up Study
NCT05603728Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy
Exactech
Observational
20,000
Reading, Yeovil, Bath, Bedford, Ipswich, Leicester, Manchester, Nottingham
2007-07-19
Recruiting
Medtronic
Observational
20,000
Birmingham, Blackpool, Bristol, Leeds, Leicester, Liverpool, London, Manchester
1983-01
Rows per page Showing 1–208 of 208
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-uk/city/leicester

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 11 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 208 of those studies with a site in Leicester.

How many clinical trials are recruiting in Leicester?

112 of the 208 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:15 UTC sync. A further 3 have not yet opened recruitment, 89 are active but closed to new participants, and 4 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Leicester), 208 studies
PhaseStudiesRecruitingShare
Phase 31125553.8%
Phase 2322015.4%
Phase 1/216117.7%
Phase 11376.3%
Observational1275.8%
Not applicable1044.8%
Phase 2/3964.3%
Phase 4421.9%

Most active sponsors

Lead sponsors with the most studies (Leicester)
Lead sponsorStudiesRecruiting
AstraZeneca166
Hoffmann-La Roche146
Merck Sharp & Dohme LLC138
Boehringer Ingelheim94
Sanofi93
GlaxoSmithKline76
Takeda76
Janssen Research & Development, LLC61
Novartis Pharmaceuticals64
Acerta Pharma BV50
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.